Youningwei: First Quarter Report for 2026

SZSIApr 28 00:00 · Announcements

Youningwei: 2025 Annual Report

SZSIApr 28 00:00 · Announcements

U-NIV: Summary of the 2025 Annual Report

SZSIApr 28 00:00 · Announcements

Youningwei (301166.SZ): The company currently has no plans for restructuring.

Gelonghui, April 22nd: Youningwei (301166.SZ) stated on the investor interaction platform that the company's controlling shareholder and actual controller remain firmly optimistic about the company’s development prospects and have no plans to transfer control. The company currently has no restructuring matters underway.

Gelonghui FinanceApr 22 09:05

Youningwei (301166.SZ): The company's independent research and development efforts are primarily concentrated in the field of antibodies and antibody-related areas.

Gelonghui, April 22nd – Youningwei (301166.SZ) stated on the investor interaction platform that the company’s self-developed efforts are mainly concentrated in the field of antibodies and antibody-related areas. Currently, the company is primarily seeking relevant target enterprises in the upstream and downstream application fields of antibodies to achieve synergistic development with existing businesses. Additionally, through participation in equity investment funds, investments are directed towards sectors such as healthcare.

Gelonghui FinanceApr 22 09:03

Youningwei (301166.SZ): Cumulative repurchase of 498,000 shares

Gelonghui, April 1st: Youningwei (301166.SZ) announced that as of March 31, 2026, the company had cumulatively repurchased 498,000 shares through its dedicated securities account for share repurchases via centralized bidding. These shares represent 0.57% of the company's total share capital. The highest transaction price was RMB 32.00 per share, and the lowest was RMB 28.61 per share. The total amount paid was RMB 15 million (excluding transaction fees).

Gelonghui FinanceApr 1 16:42